Association of prothrombin complex concentrate administration and hematoma enlargement in non–vitamin K antagonist oral anticoagulant–related intracerebral hemorrhage

Annals of Neurology

Volumn 83, Issue 1, 2018, Pages 186-196

  Gerner, Stefan T ^a,n   Kuramatsu, Joji B ^a,n   Sembill, Jochen A ^a,n   Sprügel, Maximilian I ^a,n   Endres, Matthias ^b,c,d,e,n   Haeusler, Karl Georg ^b,c,n   Vajkoczy, Peter ^b,n   Ringleb, Peter A ^f,n   Purrucker, Jan ^f,n   Rizos, Timolaos ^f,n   Erbguth, Frank ^g,n   Schellinger, Peter D ^h,n   Fink, Gereon R ^i,n   Stetefeld, Henning ^i,n   Schneider, Hauke ^j,n   Neugebauer, Hermann ^k,n   Röther, Joachim ^l,n   Claßen, Joseph ^m,n   Michalski, Dominik ^m,n   Dörfler, Arnd ^a,n   Schwab, Stefan ^a,n   Huttner, Hagen B ^a,n   Horn, Markus ⁿ   Bahner, Dirk ⁿ   Hagemann, Georg ⁿ   Rakers, Florian ⁿ   Sobesky, Jan ⁿ   Schurig, Johannes ⁿ   Zweynert, Sarah ⁿ   Bauer, Miriam ⁿ   Dohmen, Christian ⁿ   Schwarz, Michael ⁿ   Reimann, Gernot ⁿ   Reichmann, Heinz ⁿ   Rahmig, Jan ⁿ   Bogenreuther, Christina ⁿ   Hagen, Manuel ⁿ   Knappe, Ruben ⁿ   Köhrmann, Martin ⁿ   Kloska, Stephan P ⁿ   Ringwald, Jürgen ⁿ   Hamann, Gerhard F ⁿ   Michels, Peter ⁿ   Witte, Otto W ⁿ   Günther, Albrecht ⁿ   Wöhrle, Johannes C ⁿ   Alshammari, Fahid ⁿ   Grau, Armin ⁿ   Palm, Frederick ⁿ   Urbanek, Christian ⁿ   Glahn, Jörg ⁿ   Knappe, Ulrich J ⁿ   Wiendl, Heinz ⁿ   Fisse, Anna Lena ⁿ   Minnerup, Jens ⁿ   Nueckel, Martin ⁿ   Bäzner, Hansjörg ⁿ   Schwert, Henning ⁿ   Ludolph, Albert Christian ⁿ   Stösser, Sebastian ⁿ   Volkmann, Jens ⁿ   Müllges, Wolfgang ⁿ   Kraft, Peter ⁿ   Schubert, Anna Lena ⁿ   more..

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Center for Stroke Research Berlin   (Germany)

^d DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g Laboratory Medicine and Transfusion Medicine   (Germany)

^h KLINIKUM MINDEN   (Germany)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

^j DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^k UNIVERSITY OF ULM   (Germany)

^l Asklepios Clinic Altona   (Germany)

^m UNIVERSITY OF LEIPZIG   (Germany)

ⁿ NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DESMOPRESSIN; FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; RIVAROXABAN; THROMBOCYTE CONCENTRATE; TRANEXAMIC ACID; VITAMIN K GROUP; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A; HEMOSTATIC AGENT;

AGED; ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; GERMANY; HEMATOMA; HOSPITAL MORTALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANKIN SCALE; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; CHEMICALLY INDUCED; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; BLOOD PRESSURE; CEREBRAL HEMORRHAGE; COHORT STUDIES; FACTOR XA; FEMALE; GERMANY; HEMATOMA; HEMOSTATICS; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85040967783     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.25134     Document Type: Article

References (39)

1. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–962.
2. Cucchiara B, Messe S, Sansing L, et al. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 2008;39:2993–2996.
3. Biffi A, Battey TW, Ayres AM, et al. Warfarin-related intraventricular hemorrhage: imaging and outcome. Neurology 2011;77:1840–1846.
4. Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015;313:824–836.
5. Flibotte JJ, Hagan N, O'Donnell J, et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004;63:1059–1064.
6. Steiner T, Poli S, Griebe M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol 2016;15:566–573.
7. Raval AN, Cigarroa JE, Chung MK, et al. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. Circulation 2017;135:e604–e633.
8. Purrucker JC, Haas K, Rizos T, et al. Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants. JAMA Neurol 2016;73:169–177.
9. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015;373:511–520.
10. Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016;375:1131–1141.
11. Hemphill JC III, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015;46:2032–2060.
12. Siegal DM, Garcia DA, Crowther MA. How I treat target-specific oral anticoagulant-associated bleeding. Blood 2014;123:1152–1158.
13. Dzik WH. Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re-appraisal. J Thromb Haemost 2015;13(suppl 1):S187–S194.
14. Wilson D, Charidimou A, Shakeshaft C, et al. Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type. Neurology 2016;86:360–366.
15. Hagii J, Tomita H, Metoki N, et al. Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin. Stroke 2014;45:2805–2807.
16. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014;64:1128–1139.
17. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrin 2012;23:138–143.
18. Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol 2006;5:603–612.
19. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997;28:1–5.
20. Hanley DF, Lane K, McBee N, et al. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet 2017;389:603–611.
21. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med 2016;375:1033–1043.
22. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625–651.
23. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 2013;34:489–498b.
24. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467–1507.
25. Little RJA. A test of missing completely at random for multivariate data with missing values. J Am Stat Assoc 1988;83:1198–1202.
26. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007;16:219–242.
27. Frontera JA, Lewin JJ III, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 2016;24:6–46.
28. Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013;368:2113–2124.
29. Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 2013;17:R76.
30. Miesbach W, Seifried E. New direct oral anticoagulants—current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 2012;108:625–632.
31. Escolar G, Arellano-Rodrigo E, Lopez-Vilchez I, et al. Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates—in vitro studies with steady and circulating human blood. Circ J 2015;79:331–338.
32. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573–1579.
33. Mayer SA. Emergency reversal of novel oral anticoagulants: help is on the way. JAMA Neurol 2016;73:155–156.
34. Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014;371:2141–2142.
35. Dibu JR, Weimer JM, Ahrens C, et al. The role of FEIBA in reversing novel oral anticoagulants in intracerebral hemorrhage. Neurocrit Care 2016;24:413–419.
36. Carcel C, Wang X, Sato S, et al. Degree and timing of intensive blood pressure lowering on hematoma growth in intracerebral hemorrhage. Stroke 2016;47:1651.
37. Boulouis G, Morotti A, Goldstein JN, Charidimou A. Intensive blood pressure lowering in patients with acute intracerebral haemorrhage: clinical outcomes and haemorrhage expansion. Systematic review and meta-analysis of randomised trials. J Neurol Neurosurg Psychiatry 2017;88:339–345.
38. Eikelboom JW, Bosch J, Hart RG. Rapid reversal of haematoma expansion associated with vitamin K antagonists. Lancet Neurol 2016;15:535–537.
39. Dentali F, Marchesi C, Giorgi Pierfranceschi M, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011;106:429–438.